IP Verse

Optimised Pharmaceutical Formula For The Treatment Of Inflammatory Changes Of The Esophagus - EP2886108

The patent EP2886108 was granted to DR Falk Pharma on Nov 2, 2022. The application was originally filed on Dec 23, 2013 under application number EP13199278A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2886108

DR FALK PHARMA
Application Number
EP13199278A
Filing Date
Dec 23, 2013
Status
Patent Maintained As Amended
Sep 30, 2022
Grant Date
Nov 2, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELLODI PHARMACEUTICALSNov 6, 2019COOLEY UKADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2007111978
DESCRIPTIONUS2009264392
DESCRIPTIONWO2009064417
DESCRIPTIONWO2009064457
OPPOSITIONEP1595533
OPPOSITIONUS2007020330
OPPOSITIONUS2010034894
OPPOSITIONUS2011123460
SEARCHEP2151235

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- STRAUMANN ET AL., GASTROENTEROLOGY, (2010), pages 1526 - 1537-
OPPOSITION- "1217 Tablet Breaking force", US Pharmacopeia 35, The United States Pharmacopeial Convention, (20120501), pages 868 - 870-
OPPOSITION- "1217 Tablet Breaking force", US Pharmacopeia 35, The United States Pharmacopeial Convention, (20120501), pages 868 - 870, XP055650271-
OPPOSITION- "2.9.8 Bruchfestigkeit von Tabletten", European Pharmacopeia 8.0, EDQM, (20130715), page 412, XP055650019-
OPPOSITION- "2.9.8. RESISTANCE TO CRUSHING OF TABLETS", European Pharmacopeia 6.0, The Stationery Office, (20070723), pages 278 - 279, XP055650012-
OPPOSITION- ACEVES et al., "Oral Viscous Budesonide: A Potential New therapy for Eosinophilic Esophagitis in Children", Am J. Gastroenterol., (20070000), vol. 102, no. 10, pages 2271 - 2279-
OPPOSITION- Anonymous, "WHT 3ME brochure. Fully Automated 4 in 1 Tablet Testing Instrument", THE PHARMA TEST GROUP, (20180401), pages 1 - 13, URL: https://www.pharma-test.de/wp-content/uploads/2018/04/ptag-80-21000-wht-3me-e.pdf-
OPPOSITION- Anonymous, "WHT 3ME brochure. Fully Automated 4 in 1 Tablet Testing Instrument", THE PHARMA TEST GROUP, (20180401), pages 1 - 13, URL: https://www.pharma-test.de/wp-content/uploads/2018/04/ptag-80-21000-wht-3me-e.pdf, XP055650001-
OPPOSITION- DILGER et al., "Active Eosinophilic Esophagitis Is Associated with Impaired Elimination of Budesonide by Cytochrome P450 3A Enzymes", Digestion, (20130400), vol. 87, no. 2, pages 110 - 117-
OPPOSITION- DOHIL et al., Gastroenterology, (20100724), vol. 139, no. 2, pages 418 - 429. e1-
OPPOSITION- DOHIL et al., Gastroenterology, (20100724), vol. 139, no. 2, pages 418 - 429. e1, XP027165010-
OPPOSITION- DR. SCHLEUNIGER, "Key factors influencing measured tablet hardness", Pharmatron, (20110000), pages 1 - 5, URL: https://www.pharmaceutical-networking.com/wp-content/uploads/2012/06/Key-Factors-Influencing-Measured-Tablet-Hardness.pdf-
OPPOSITION- DR. SCHLEUNIGER, "Key factors influencing measured tablet hardness", Pharmatron, (20110000), pages 1 - 5, URL: https://www.pharmaceutical-networking.com/wp-content/uploads/2012/06/Key-Factors-Influencing-Measured-Tablet-Hardness.pdf, XP055649995-
OPPOSITION- KRISHNA et al., "Treatment of Eosinophilic Esophagitis: Oral Viscous Budesonide Superior to Swallowed Fluticasone Spray?", Gastroenterol Hepatol., (20110100), vol. 7, no. 1, pages 55 - 59-
OPPOSITION- KRISHNA et al., "Treatment of Eosinophilic Esophagitis: Oral Viscous Budesonide Superior to Swallowed Fluticasone Spray?", Gastroenterol Hepatol., (20110100), vol. 7, no. 1, pages 55 - 59, XP055618941-
OPPOSITION- Rowe et al., HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, London, (20060000), pages 53 - 55, 742-743-
OPPOSITION- Rowe et al., HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, London, (20060000), pages 53 - 55, 742-743, XP055618936-
OPPOSITION- TAYEBI et al., "Formulation and Evaluation of a Novel Matrix-Type Orally Disintegrating Ibuprofen Tablet", Iran J Pharm Res, (20110000), vol. 10, no. 3, pages 469 - 479-
OPPOSITION- TAYEBI et al., "Formulation and Evaluation of a Novel Matrix-Type Orally Disintegrating Ibuprofen Tablet", Iran J Pharm Res, (20110000), vol. 10, no. 3, pages 469 - 479, XP055649984-
OPPOSITION- ACEVES et al., "Oral Viscous Budesonide: A Potential New therapy for Eosinophilic Esophagitis in Children", Am J. Gastroenterol., (20070000), vol. 102, no. 10, pages 2271 - 2279, XP029296938
OPPOSITION- DILGER et al., "Active Eosinophilic Esophagitis Is Associated with Impaired Elimination of Budesonide by Cytochrome P450 3A Enzymes", Digestion, (20130400), vol. 87, no. 2, pages 110 - 117, XP008183704

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents